An Engel condition for orderable groups

Let m,n be positive integers, v a multilinear commutator word and w=v^m. We prove that if G is an orderable group in which all w-values are n-Engel, then the verbal subgroup v(G) is locally nilpotent. We also show that in the particular case where v=x the group G is nilpotent (rather than merely locally nilpotent)

Quantum-thermal annealing with cluster-flip algorithm

A quantum-thermal annealing method using a cluster-flip algorithm is studied in the two-dimensional spin-glass model. The temperature (T) and the transverse field (Gamma) are decreased simultaneously with the same rate along a linear path on the T-Gamma plane. We found that the additional pulse of the transverse field to the frozen local spins produces a good approximate solution with a low computational cost.Comment: 4 pages, 3 figure

Theoretical analysis of the experiments on the double-spin-chain compound -- KCuCl3_3

We have analyzed the experimental susceptibility data of KCuCl$_3$ and found that the data are well-explained by the double-spin-chain models with strong antiferromagnetic dimerization. Large quantum Monte Carlo calculations were performed for the first time in the spin systems with frustration. This was made possible by removing the negative-sign problem with the use of the dimer basis that has the spin-reversal symmetry. The numerical data agree with the experimental data within 1% relative errors in the whole temperature region. We also present a theoretical estimate for the dispersion relation and compare it with the recent neutron-scattering experiment. Finally, the magnitude of each interaction bond is predicted.Comment: 4 pages, REVTeX, 5 figures in eps-file

pGlu-serpinin protects the normotensive and hypertensive heart from ischemic injury

Serpinin peptides derive from proteolytic cleavage of Chromogranin-A at C-terminus. Serpinin and the more potent pyroglutaminated-Serpinin (pGlu-Serp) are positive cardiac beta-adrenergic-like modulators, acting through β1-AR/AC/cAMP/PKA pathway. Since in some conditions this pathway and/or other pro-survival pathways, activated by other Chromogranin-A fragments, may cross-talk and may be protective, here we explored whether pGlu-Serp cardioprotects against ischemia/reperfusion injury under normotensive and hypertensive conditions. In the latter condition cardioprotection is often blunted because of the limitations on pro-survival Reperfusion-Injury-Salvage-Kinases (RISK) pathway activation. The effects of pGlu-Serp were evaluated on infarct size (IS) and cardiac function by using the isolated and Langendorff perfused heart of normotensive (WKY) and spontaneously hypertensive (SHR) rats exposed to ischemic pre-conditioning (PreC) and post-conditioning (PostC). In both WKY and SHR rat, pGlu-Serp induced mild cardioprotection in both PreC and in PostC. pGlu-Serp administered at the reperfusion (Serp-PostC) significantly reduced IS, being more protective in SHR than in WKY. Conversely, developed Left Ventricular Pressure (LVDevP) post-ischemic recovery was greater in WKY than in SHR. pGlu-Serp-PostC reduced contracture in both strains. Co-infusion with specific RISK inhibitors (PI3K/AkT, MitoK(ATP) channels, and PKC) blocked the pGlu-Serp-PostC protective effects. To show direct effect on cardiomyocytes, we pre-treated H9c2 with pGlu-Serp which were thus protected against hypoxia/reoxygenation. These results suggest pGlu-Serp as a potential modulatory agent implicated in the protective processes which can limit infarct size and overcome the hypertension-induced failure of PostC

Vanishing of the negative-sign problem of quantum Monte Carlo simulations in one-dimensional frustrated spin systems

The negative-sign problem in one-dimensional frustrated quantum spin systems is solved. We can remove negative signs of the local Boltzmann weights by using a dimer basis that has the spin-reversal symmetry. Validity of this new basis is checked in a general frustrated double-spin-chain system, namely the J_0-J_1-J_2-J_3 model. The negative sign vanishes perfectly for $J_0 + J_1 \leq J_3$.Comment: 4 pages, REVTeX, 4 figures in eps-file

ADAMTS2 gene dysregulation in T/myeloid mixed phenotype acute leukemia.

Background: Mixed phenotype acute leukemias (MPAL) include acute leukemias with blasts that express antigens of more than one lineage, with no clear evidence of myeloid or lymphoid lineage differentiation. T/myeloid (T/My) MPAL not otherwise specified (NOS) is a rare leukemia that expresses both T and myeloid antigens, accounting for less than 1% of all leukemias but 89% of T/My MPAL. From a molecular point of view, very limited data are available on T/My MPAL NOS. Case presentation: In this report we describe a T/My MPAL NOS case with a complex rearrangement involving chromosomes 5 and 14, resulting in overexpression of the ADAM metallopeptidase with thrombospondin type 1 motif, 2 (ADAMTS2) gene due to its juxtaposition to the T cell receptor delta (TRD) gene segment. Conclusion: Detailed molecular cytogenetic characterization of the complex rearrangement in the reported T/My MPAL case allowed us to observe ADAMTS2 gene overexpression, identifying a molecular marker that may be useful for monitoring minimal residual disease. To our knowledge, this is the first evidence of gene dysregulation due to a chromosomal rearrangement in T/My MPAL NOS. Keywords: Mixed phenotype acute leukemia, ADAMTS2, TRD, Complex chromosomal rearrangement, Promoter swapping, Gene dysregulatio

Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia.

In this study we performed absolute quantification of the PML-RARA transcript by droplet digital polymerase chain reaction (ddPCR) in 76 newly diagnosed acute promyelocytic leukemia (APL) cases to verify the prognostic impact of the PML-RARA initial molecular burden. ddPCR analysis revealed that the amount of PML-RARA transcript at diagnosis in the group of patients who relapsed was higher than in that with continuous complete remission (CCR) (272 vs 89.2 PML-RARA copies/ng, p = 0.0004, respectively). Receiver operating characteristic analysis detected the optimal PML-RARA concentration threshold as 209.6 PML-RARA/ng (AUC 0.78; p < 0.0001) for discriminating between outcomes (CCR versus relapse). Among the 67 APL cases who achieved complete remission after the induction treatment, those with > 209.6 PML-RARA/ng had a worse relapse-free survival (p = 0.0006). At 5-year follow-up, patients with > 209.6 PML-RARA/ng had a cumulative incidence of relapse of 50.3% whereas 7.5% of the patients with suffered a relapse (p < 0.0001). Multivariate analysis identified the amount of PML-RARA before induction treatment as the sole independent prognostic factor for APL relapse. Our results show that the pretreatment PML-RARA molecular burden could therefore be used to improve risk stratification in order to develop more individualized treatment regimens for high-risk APL cases

The scientist' experience in participated science communication

Since 2006 a small group of researchers from the Italian National Institute for Nuclear Physics started to realized one of the first European Researchers' Night in Europe: a one night-event, supported by the European Commission, that falls every last Friday of September to promote the researcher's figure and its work. Today, after thirteen editions, the project has evolved by involving more than 60 scientific partners and more than 400 events/year spread from the North to the South of Italy in 30 cities, captivating more than 50.000 attendees with a not negligible impact on the people and the press. During the years, the project has followed and sometimes anticipated the science communication trend, and BEES (BE a citizEn Scientist) is the last step of this long and thrilling evolution that brought to a huge public engagement in our territory. The experience, the methodology, and the major successful examples of the organized events are presented together with the results of the long term project impact